Home / US Kidney Statistics / Kidney Disease Statistics in Alaska, USA

US Kidney Statistics

Kidney Disease Statistics in Alaska, USA

Kidney disease is one of the most serious and fastest-growing public health threats in Alaska. More than 1,000 residents are living with end-stage kidney failure, and tens of thousands more have earlier stages of chronic kidney disease. The burden reaches every part of the state, from Anchorage to remote villages accessible only by small aircraft, yet the condition remains widely underdiagnosed, underfunded, and overlooked.

The data show a crisis defined by rapid growth, limited access to care, and stark inequities. Since 2011, the number of Alaskans with kidney failure has risen 41%, the fastest increase in the nation over the past three decades. The state has no in-state transplant centers, requiring patients to travel thousands of miles for surgery, while rural isolation further restricts treatment. Risks are disproportionately high among Black, American Indian, and Alaska Native communities, where diabetes, hypertension, obesity, and limited healthcare access compound the problem. The financial toll is severe: most dialysis patients cannot work, and out-of-pocket costs average more than $7,000 a year against modest incomes. Yet many cases are preventable, as diabetes and high blood pressure account for nearly three-quarters of kidney failure, and prevention can save both lives and substantial healthcare costs.

The statistics that follow detail the scale, disparities, and consequences of kidney disease across the state.

Overview: Kidney Failure in Alaska

Kidney failure — also called End-Stage Renal Disease (ESRD) — is a critical and growing public health challenge in Alaska. The following statistics capture the scale of kidney failure across multiple reporting years, illustrating both the current burden on Alaskans and a troubling upward trend. Notably, Alaska has no transplant centers, meaning all Alaskans who require a kidney transplant must travel out of state for the procedure.

Current Burden of Kidney Failure (2024 Report)

The 2024 AKF report represents the most recent snapshot of kidney failure prevalence in Alaska. Key figures include:

Alaskans living with kidney failure (total): 1,066
Alaskans on dialysis: 658
Alaskans living with a kidney transplant: 408
New cases diagnosed in 2021 (most recent available): 143
Of those new cases — began dialysis: 143; received a kidney transplant: 0
Increase in total kidney failure cases since 2011: 41%

The 2024 data shows a continuing rise in Alaskans living with kidney failure. The absence of any transplant recipients among new 2021 diagnoses reflects Alaska’s lack of in-state transplant infrastructure — a structural gap that forces all transplant-eligible patients to seek care out of state. The 41% increase since 2011 signals an accelerating burden.

Kidney Failure Trend Across Reporting Years

Comparing data across the 2021, 2022, and 2024 AKF reports reveals a persistent and worsening trend.

Report Year	Total Living with Kidney Failure	On Dialysis	Living with Transplant	New Cases (Year of Data)	% Increase Since Baseline
2021 Report	1,041	665	376	155 (2018 data)	+36.3% since 2009 (implied)
2022 Report	1,065	670	395	154 (2019 data)	+36.3% since 2009
2024 Report	1,066	658	408	143 (2021 data)	+41% since 2011

The total number of Alaskans living with kidney failure has remained stubbornly above 1,000 across all reporting periods, while transplant recipients have gradually grown. The decline in new cases from 155 (2018) to 143 (2021) may reflect improved early intervention or reporting variation, but the overall burden continues to rise.

Leading Causes of Kidney Failure

Diabetes and high blood pressure are the two dominant drivers of kidney failure in Alaska, consistent with national trends. Together they account for the overwhelming majority of cases. Early detection and management of these conditions is widely recognized as the most effective tool to prevent kidney failure from developing.

Cause	2022 Report (% of Cases)	2024 Report (% of Cases)
Diabetes	47%	44%
High Blood Pressure	28%	29%
Combined Total	75%	73%

Diabetes alone accounts for nearly half of all kidney failure cases in Alaska, and together with high blood pressure these two conditions drive nearly three-quarters of all cases. Both conditions are largely preventable and manageable, making upstream public health interventions critical. The slight decrease in diabetes as a cause (47% to 44%) may indicate modest progress in diabetes-related kidney protection.

Racial and Ethnic Disparities in Kidney Failure

Kidney failure does not affect all Alaskans equally. People of color face significantly higher rates of kidney failure, reflecting broader inequities in social determinants of health, access to care, and exposure to risk factors such as diabetes and hypertension. The following table compares likelihood of developing kidney failure relative to White Americans across two reporting periods.

Relative Risk of Kidney Failure by Race/Ethnicity

Group	Likelihood vs. White Americans (2022 Report)	Likelihood vs. White Americans (2024 Report)
Black Americans	3.4x greater	4.3x greater
American Indians	1.9x greater	2.3x greater
Asian Americans	1.3x greater	1.6x greater
Hispanic/Latino (vs. non-Hispanic/Latino)	1.5x greater	2.2x greater

Disparities have widened across nearly every racial and ethnic group between the 2022 and 2024 reports. The most striking increase is among Black Americans, whose relative risk grew from 3.4x to 4.3x. American Indian populations face 2.3x the risk of White Americans — a gap that is particularly relevant in Alaska given the significant Alaska Native population. These figures demand targeted public health strategies for communities of color.

American Indian and Alaska Native (AI/AN) Kidney Disease Burden

AI/AN communities face compounding risk factors that drive disproportionately high rates of kidney disease, including kidney cancer. The following highlights the key data points from national and Alaska-specific research:

AI/AN populations have approximately 80% higher kidney cancer incidence rates compared to White populations.
Kidney cancer death rates have remained stable in AI/AN populations while declining among White populations.
Kidney failure rates are about 3.5 times higher in the AI/AN community than in Whites.
The prevalence of diabetes in AI/ANs is 2–3 times higher than that of Whites — AI/ANs have the highest rates of Type 2 diabetes of any major racial/ethnic group in the U.S.
AI/ANs are 1.5 times more likely to be obese than White adults.
Roughly 25–30% of AI/AN adults smoke cigarettes; AI/ANs are more likely to smoke than other racial or ethnic groups.
Hypertension prevalence in AI/ANs is 23% higher than in Whites.
Gaps have been attributed to lower socioeconomic status, decreased access to healthcare, and lack of appropriate medical care leading to later-stage diagnoses.

The convergence of elevated diabetes rates, hypertension, obesity, smoking, and reduced healthcare access creates a perfect storm for kidney disease in AI/AN communities. These disparities are not inevitable — they are driven by systemic inequities that require targeted policy and healthcare investment.

Chronic Kidney Disease (CKD) Prevalence in Alaska

Chronic kidney disease is the precursor to kidney failure, and its prevalence reflects the future pipeline of patients who may reach end-stage disease. Alaska’s CKD rates are measured by the percentage of adults ever told by a health professional that they have kidney disease, excluding kidney stones, bladder infections, and incontinence.

Overall CKD Rate

Alaska’s overall CKD burden places it among the most affected states in the nation:

Overall Alaska CKD rate among adults: 3.2%
Alaska national rank (overall): 4th highest in the nation
Data year: 2024

Alaska ranks 4th in the nation for overall CKD prevalence — a troubling position for a state with limited nephrology infrastructure and no in-state transplant centers.

CKD Prevalence by Sex

Sex	Alaska CKD Rate	National Rank
Female	4.0%	18 out of 49 states
Male	2.5%	1 out of 49 states (highest in nation)

Alaska’s male CKD rate ranks highest in the nation — a striking finding that may reflect occupational exposures, lifestyle factors, or reduced engagement with preventive care among Alaskan men.

CKD Prevalence by Age Group

CKD rates increase significantly with age. The following figures show Alaska’s rate and national ranking for each age bracket:

Ages 18–44: 1.4% — ranked 24 out of 44 states
Ages 45–64: 3.0% — ranked 3 out of 49 states
Ages 65+: 8.0% — ranked 12 out of 49 states

CKD rates increase sharply with age, with 8% of Alaskans 65 and older reporting diagnosis. The 45–64 age group ranks 3rd highest nationally — suggesting Alaska’s middle-aged population faces particular kidney disease burdens, possibly tied to comorbidities like diabetes and hypertension.

CKD Prevalence by Race/Ethnicity

Group	Alaska CKD Rate	Notes
Non-Hispanic White adults	3.3%	Ranked 6 out of 49 states
Non-Hispanic American Indian/Alaska Native adults	3.9%	Not ranked (small sample)

American Indian/Alaska Native adults in Alaska report CKD at a rate nearly a full percentage point higher than White adults. Given the known underdiagnosis of kidney disease in this population, the true burden is likely higher than these self-reported figures suggest.

CKD Prevalence by Income

Income is strongly associated with kidney disease rates. Lower income is consistently linked to higher CKD prevalence across Alaska:

Less than $25,000/year: 6.6% — ranked 12 out of 48 states
$25,000–$49,999/year: 4.0% — ranked 2 out of 49 states
$50,000–$74,999/year: 4.3% — ranked 22 out of 45 states
$100,000–$149,999/year: 2.4% — ranked 14 out of 40 states
$150,000 or more/year: 2.7% — ranked 27 out of 31 states

Alaskans earning less than $25,000 annually have a CKD rate (6.6%) more than 2.4 times that of the highest income bracket (2.7%). This income gradient mirrors national patterns and reflects how poverty limits access to preventive care, healthy food, and treatment adherence.

CKD Prevalence by Education

Education Level	Alaska CKD Rate	National Rank
High school diploma/GED	3.6%	9 out of 49 states
Some college/technical school	4.0%	7 out of 49 states
College/technical school graduate	3.4%	25 out of 49 states

Alaska consistently ranks in the top 10 nationally for CKD rates among non-college graduates. The highest CKD rate falls in the ‘some college’ category, which may reflect demographic characteristics of that cohort in Alaska. Educational attainment plays a meaningful protective role overall.

CKD Prevalence by Disability Status

Adults living with disabilities face substantially elevated CKD rates. The data below shows Alaska’s rates and national rankings across disability types:

Difficulty hearing: 8.2% — ranked 10 out of 47 states
Difficulty seeing: 11.2% — ranked 26 out of 44 states
Difficulty with cognition: 5.5% — ranked 13 out of 49 states
Difficulty with mobility: 9.8% — ranked 7 out of 49 states
Difficulty with self-care: 9.0% — ranked 4 out of 47 states
Independent living difficulty: 9.6% — ranked 17 out of 49 states
No disability: 1.7% — ranked 4 out of 49 states

Alaskans with disabilities face kidney disease rates 3 to 6 times higher than those without disabilities. This overlap likely reflects shared underlying conditions (e.g., diabetes, hypertension) and may also reflect the bidirectional relationship between kidney disease and disability. Alaska’s rank of 4th highest nationally for CKD even in people without disabilities is notable and concerning.

CKD Prevalence by Geography

Geography Type	Alaska CKD Rate	National Rank
Metropolitan areas	3.1%	5 out of 49 states
Non-metropolitan areas	3.3%	6 out of 43 states

Both urban and rural Alaskans face comparably high CKD rates nationally. This is unusual, as CKD tends to be more prevalent in rural areas nationally; in Alaska, high urban rates suggest systemic factors beyond geography alone.

CKD Incidence, Prevalence, and Mortality Trends

Alaska has experienced some of the most dramatic increases in CKD burden in the United States over recent decades, outpacing nearly every other state in incidence growth, prevalence growth, and mortality rate increases.

Increase in CKD incidence (30-year study period): +156% — greatest increase nationally
Increase in CKD prevalence: +73% — greatest increase nationally
Increase in CKD mortality rate (1990–2019): +354% — greatest increase nationally
National CKD mortality rate per 100,000 rose from 13 (1990) to 33 (2019); no state experienced a decrease in prevalence over this period

Alaska leads the nation in the rate of increase for CKD incidence, prevalence, and mortality — a deeply alarming finding. A 354% increase in CKD mortality over 30 years far surpasses the national norm. These trends demand urgent and sustained public health attention.

Annual Kidney Disease Mortality in Alaska

Year	Deaths	Death Rate (per 100,000)
2019	62	10.7
2020	66	10.8
2021	84	14.0
2022	97	14.7
2023	86	12.4

Annual kidney disease deaths in Alaska roughly doubled from 62 in 2019 to 97 in 2022 before declining slightly in 2023. The spike in 2021–2022 coincides with the COVID-19 pandemic period, during which kidney complications were widely documented. Even the 2023 figure (86 deaths) remains substantially above pre-2021 levels.

Kidney Disease in the Context of Alaska Chronic Disease

Kidney disease does not exist in isolation — it is deeply intertwined with other chronic conditions, including diabetes, heart disease, high blood pressure, and obesity. Understanding the full chronic disease landscape in Alaska helps frame the systemic risks faced by Alaskans.

Prevalence of Chronic Conditions Among Alaska Adults

Chronic Condition	Prevalence (2024)	Prevalence (2021)
High Blood Pressure	33%	31%
High Cholesterol	30%	27%
Arthritis	27%	24%
Asthma	17%	15%
Cancer	10%	10%
Diabetes	9%	8%
COPD	6%	6%
Heart Disease	6%	5%
Kidney Disease	3%	2%
Stroke	3%	3%

The two leading causes of kidney failure — high blood pressure (33%) and diabetes (9%) — affect a combined 42% of Alaska adults. Kidney disease itself has grown from 2% to 3% prevalence between 2021 and 2024. With both primary risk conditions trending upward, the pipeline of future kidney disease patients will likely continue to grow.

Top Causes of Death in Alaska

Kidney disease intersects with and is worsened by many of Alaska’s leading causes of death:

Cancer: 1,137 deaths (2024) vs. 1,091 (2021) — leading cause of death in Alaska
Heart Disease: 821 deaths (2024) vs. 1,011 (2021)
Unintentional Injury: 667 deaths (2024) vs. 591 (2021)
COVID-19: 232 deaths (2024) vs. 762 (2021)
Stroke: 227 deaths (2024) vs. 253 (2021)
Chronic Lower Respiratory Disease: 222 deaths (2024) vs. 237 (2021)
Suicide: 171 deaths (2024) vs. 220 (2021)
Chronic Liver Disease and Cirrhosis: 138 deaths (2024) vs. 189 (2021)
Diabetes: 134 deaths (2024) vs. 183 (2021) — a direct driver of kidney failure
Alzheimer’s Disease: 101 deaths (2024) vs. 135 (2021)

Diabetes, which is the leading cause of kidney failure in Alaska, appears directly as a top-10 cause of death with 134 deaths in 2024. Heart disease and stroke — conditions that share risk factors with and are worsened by kidney disease — account for nearly 1,050 deaths combined in 2024. The interconnected burden of these conditions amplifies the public health case for kidney disease prevention.

Risk Factors for Kidney Disease Among Alaskans

Multiple behavioral, metabolic, and environmental risk factors increase the likelihood of developing kidney disease. Alaska’s population faces many of these risk factors at elevated rates compared to national averages.

Behavioral and Metabolic Risk Factors

Risk Factor	Adults (2024)	Adults (2021)	High School Students (2023)
Overweight or obese	69%	68%	33%
Drink 1+ sugary drink/day	26%	18%	53%
No physical activity	18%	21%	82% (< 60 min/day)
Currently smoke cigarettes	15%	17%	7%
Currently vape	8%	N/A (2019: 26% teens)	17%

Nearly 70% of Alaska adults are overweight or obese — a primary risk factor for both diabetes and hypertension, the top two causes of kidney failure. The dramatic rise in sugary drink consumption among adults (18% to 26%) is concerning, as sugar intake is strongly linked to obesity, diabetes, and elevated uric acid levels. Among high schoolers, 82% fail to meet daily physical activity recommendations, portending elevated chronic disease risk in the next generation.

The Role of Uric Acid (GOCADAN Study Findings)

The Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study examined 1,078 predominantly Inupiat Eskimo participants in the Norton Sound region of Alaska (recruited 2000–2004), providing unique data on kidney disease risk in an Alaska Native population. Key findings:

7% (n=75) of GOCADAN participants had prevalent CKD (eGFR < 60 mL/min/1.73 m²).
21% (n=230) had prevalent hypertension.
Uric acid (UA) was independently associated with prevalent CKD: adjusted odds ratio of 2.04 (95% CI: 1.62–2.56) after adjustment for all covariates.
UA was independently associated with prevalent hypertension: adjusted odds ratio of 1.24 (95% CI: 1.06–1.46).
Participants with the highest UA tertile (5.8–11.8 mg/dL) had 14% CKD prevalence vs. 3% in the lowest tertile (≤4.6 mg/dL).
This Alaska Native population had lower rates of diabetes and CKD than the general U.S. population, which researchers attributed in part to relatively low rates of diabetes in the cohort.

UA Tertile	UA Range (mg/dL)	% with CKD (eGFR < 60)	Hypertension %	Mean eGFR
Tertile 1 (lowest)	≤4.6	3%	12%	92 mL/min/1.73 m²
Tertile 2	4.7–5.7	4%	17%	88 mL/min/1.73 m²
Tertile 3 (highest)	5.8–11.8	14%	35%	79 mL/min/1.73 m²

This study provides compelling evidence that elevated serum uric acid is an independent risk factor for both CKD and hypertension in Alaska Native populations — even after controlling for age, sex, BMI, diabetes, smoking, and lipids. The nearly 5-fold increase in CKD prevalence from the lowest to highest uric acid tertile is striking, and points to uric acid as a potentially modifiable risk factor deserving clinical attention in this population.

Financial Burden of Kidney Disease

Kidney failure imposes extraordinary financial costs on patients, insurers, and the Medicare program. The combination of treatment demands, inability to work, and high out-of-pocket costs creates devastating financial hardship for many Alaskans with kidney failure.

Medicare Costs for Kidney Disease Patients

The annual Medicare cost per patient varies dramatically based on treatment stage:

Pre-kidney failure (CKD) patient: $25,920 per year
Dialysis patient: $79,439 per year
First year after kidney transplant: $23,308 per year
In 2018, Medicare spending for ESRD beneficiaries nationally totaled $36.6 billion — 7.2% of all Medicare costs, despite ESRD patients comprising less than 1% of the total Medicare population.
A patient on hemodialysis costs Medicare more than $93,000 per year.
For each kidney disease patient who does not reach kidney failure, Medicare saves an estimated $250,000.

The economic case for kidney disease prevention is overwhelming. Every Alaskan who avoids progressing to kidney failure represents an estimated $250,000 in Medicare savings — not to mention the immeasurable quality-of-life benefit to the patient. The extreme cost concentration (ESRD patients <1% of Medicare population generating 7.2% of costs) underscores why early intervention is both morally and fiscally imperative.

Patient Financial Hardship

Financial Hardship Metric	Value
Dialysis patients who cannot work	> 80%
Average annual income of AKF-assisted patients	Less than $25,000
Average annual out-of-pocket costs for dialysis patients	More than $7,000
Out-of-pocket costs as % of average patient income	~28%

Dialysis patients face an average annual out-of-pocket burden of over $7,000 — more than a quarter of their typical income of under $25,000. This financial squeeze is further compounded by the fact that more than 80% cannot work, leaving them almost entirely dependent on government benefits and charitable assistance.

American Kidney Fund (AKF) Charitable Assistance in Alaska

Metric	2020 (2021 Report)	2021 (2022 Report)	2023 (2024 Report)
Alaskans receiving AKF grants	92	79	74
Total AKF charitable assistance	$396,000	$437,363	$449,505

AKF charitable assistance in Alaska has grown in dollar terms even as the number of recipients has slightly declined, suggesting average grant amounts per patient are increasing — likely due to rising healthcare costs. Together, these grants fill critical gaps in coverage for Alaska’s most financially vulnerable dialysis and transplant patients.

AKF Assistance by Race/Ethnicity

AKF provides financial assistance disproportionately to minority patients, reflecting the higher burden of kidney failure in these communities:

White Americans with kidney failure: AKF assists 1 out of every 21 (2024 report) vs. 1 out of every 17 (2022 report)
Black Americans with kidney failure: AKF assists 1 out of every 12 (2024 report) vs. 1 out of every 10 (2022 report)
Hispanic/Latino Americans with kidney failure: AKF assists 1 out of every 10 in both reporting periods

AKF reaches a proportionally larger share of Black and Hispanic/Latino patients than White patients, reflecting both greater need in those communities and targeted outreach. The fact that even 1 in 10 patients in these groups requires charitable assistance for basic insurance premiums speaks to the deep financial vulnerability of kidney failure patients of color.

Insurance Breakdown of AKF-Assisted Patients

Insurance Type	2021 (% of AKF recipients)	2023 (% of AKF recipients)
Medicare Part B	36.8%	44.6%
Medigap	31.1%	23.4%
Employer group health plans (incl. COBRA)	18.9%	17.2%
Commercial plans	10.5%	N/A
Exchange	3.4%	N/A
Medicare Advantage	1.2%	1.4%
Annuity	1.5%	N/A
Medicaid (states charging premiums)	0.1%	N/A

The shift toward Medicare Part B (37% to 45%) and away from Medigap (31% to 23%) among AKF-assisted patients may reflect demographic aging of the ESRD population and changes in insurance coverage choices. Medicare remains the dominant insurer for this population.

Preventive Care and Early Detection Gaps

Early detection of CKD and its risk factors is critical to preventing progression to kidney failure. Yet many Alaskans are not receiving recommended preventive care, creating a large pool of undiagnosed or poorly managed kidney disease.

Preventive Care Gap	2024 Figure	2021 Figure
Adults without diabetes who had no blood sugar test in last 3 years	24%	54%
Women 50–74 with no mammogram in past 2 years	32%	39% (women 40+)
Adults 45–75 not meeting colorectal cancer screening recommendations	36%	30% (adults 50–75)
Adults 18–64 with no health care coverage	10%	11%
Adults with no routine checkup in past year	30%	N/A

The reduction in adults skipping blood sugar testing (54% in 2021 to 24% in 2024) is a significant positive trend — diabetes detection is essential for kidney protection. However, 24% of Alaskans without diabetes still went at least 3 years without a blood sugar test. Given that nearly half of kidney failure cases stem from diabetes, regular blood sugar screening remains a critical prevention gap.

Social Determinants Affecting Health Access

Structural and social factors compound the difficulty of accessing consistent kidney disease prevention and care across Alaska:

Adults who could not afford to see a doctor in past 12 months: 12% (2024) vs. 13% (2021)
Adults experiencing housing insecurity: 12% (2024)
Adults experiencing food insecurity: 13% (2024)
Rural community housing units without water and sewer: 14% (2024) vs. 15% (2021)
Alaskans living in poverty: 15% (2024) vs. 16% (2021)
High school students not graduating in 4 years: 22% (both periods)
Adults experiencing social isolation/loneliness: 33% (2024)

The structural barriers to health in Alaska are substantial. Rural communities lacking basic water and sewer infrastructure face risks of infectious disease and contaminated water exposure — both of which can damage kidneys. Food insecurity, poverty, and inability to afford care all impede the consistent management needed to slow kidney disease progression.

Kidney Function Decline in AI/AN Populations with Diabetes

A real-world cohort study using Providence Health System records (2013–2022) compared Major Adverse Kidney Events (MAKE) between American Indian/Alaska Native (AI/AN) and White non-Hispanic (WNH) adults with diabetes. MAKE was defined as ≥40% decline in eGFR, eGFR dropping below 15 mL/min/1.73 m², dialysis or transplant initiation, or all-cause death.

Metric	AI/AN Population	White Non-Hispanic Population
Study population (adults with diabetes)	N = 6,103	N = 354,283
Mean age	54 ± 15 years	62 ± 14 years
Mean HbA1c	7.4 ± 2.2%	6.9 ± 1.8%
MAKE event rate	26% (n=1,584)	24% (n=85,920)
Adjusted MAKE hazard ratio for AI/AN race	1.20 (95% CI: 1.15–1.27)	Reference group

Additional findings from adjusted Cox regression models:

Social Vulnerability Index was associated with higher MAKE risk (HR 1.03, 95% CI: 1.00–1.05).
Hospitalizations were associated with higher MAKE risk (HR 1.7, 95% CI: 1.54–1.89).
Primary care visits were associated with lower MAKE risk (HR 0.80, 95% CI: 0.72–0.90).

Even after adjusting for clinical and residential factors, AI/AN adults with diabetes face 20% higher risk of major adverse kidney events than White peers. Notably, AI/AN patients in this cohort were younger (54 vs. 62 years) but had worse glycemic control. The finding that primary care visits reduce MAKE risk underscores the protective value of consistent healthcare access — a significant equity issue in a state where many AI/AN communities are only reachable by small aircraft.

Kidney Disease, Disability, and Social Security Benefits in Alaska

Kidney failure is recognized by the Social Security Administration (SSA) as a disabling condition. The financial and employment consequences of kidney failure are severe, and many Alaskans depend on Social Security Disability Insurance (SSDI) for income and healthcare coverage.

Alaska Medicare patients with CKD diagnosed: 8.74% of Medicare population
Alaska Medicare patients on dialysis: 638
People on dialysis who cannot work: more than 80%
Initial SSDI denial rate (national): more than 60%
SSA Blue Book listing for dialysis patients: automatically considered disabled from date dialysis began
SSA listing for kidney transplant recipients: automatically disabled for 12 months post-transplant
Maximum SSDI attorney contingency fee: 25% of back pay, not to exceed $7,200

The automatic disability designation for dialysis patients — combined with the 5-month SSDI waiting period that may already be satisfied at the time of application — means many Alaskans on dialysis may have immediate eligibility for benefits they are not accessing. The 60%+ initial denial rate nationally highlights the importance of persistent appeals and legal representation.

National Context for Alaska Kidney Disease

Understanding Alaska’s kidney disease burden requires context against national statistics. The U.S. faces its own kidney disease crisis, and Alaska’s rates — already severe — represent an accelerated version of national trends.

National Kidney Disease Statistic	Value
Americans with CKD	More than 37 million (1 in 7 adults)
Adults with CKD who don’t know they have it	As many as 9 out of 10
Americans with kidney failure (total)	More than 785,000
Americans on dialysis	~555,000
Americans living with kidney transplants	~230,000
New kidney failure cases diagnosed per month	~11,000
Increase in kidney failure since 2000	More than 100%
CKD mortality rate per 100,000 (1990)	13
CKD mortality rate per 100,000 (2019)	33
1/3 of 2018 kidney failure diagnoses…	…received little or no pre-ESRD care
Black Americans’ kidney failure risk vs. White Americans	3.4x more likely
Hispanic Americans’ kidney failure risk vs. non-Hispanic	1.5x more likely

Alaska’s 41% increase in kidney failure since 2011 mirrors the national doubling since 2000, but at a compressed timescale. The staggering figure that 9 out of 10 CKD patients don’t know they have it — combined with Alaska’s 4th-highest CKD rate nationally — suggests a large pool of undiagnosed Alaskans who are silently progressing toward kidney failure.

Legislative and Policy Context

Several federal legislative initiatives have been proposed to address the kidney disease burden in Alaska and nationally:

Living Donor Protection Act (LDPA): Protects living organ donors against discrimination in life, disability, or long-term care insurance pricing, and codifies living donation under the Family and Medical Leave Act.
Improving Access to Home Dialysis Act: Expands patient access to home dialysis, removing barriers based on geographic location — directly relevant to remote Alaskan communities.
CDC Chronic Kidney Disease Initiative: The National Kidney Foundation has sought $15 million in appropriations for CKD prevention and early detection.
NIDDK Funding: Additional funding sought for the National Institute of Diabetes, Digestive and Kidney Disease to expand research and improve treatments for kidney disease.
Organ Transplantation Transparency, Accessibility, and Reform Act (OTTAR): Seeks oversight and accountability for the organ procurement and transplantation system, with particular attention to communities at high risk for kidney failure but with low access to transplantation — a description that fits much of Alaska.

OTTAR and the Home Dialysis Access Act are particularly relevant to Alaska, where the lack of in-state transplant centers and the geographic isolation of many communities create structural barriers that legislation could help address. Alaska’s status as the state with the greatest national increases in CKD incidence, prevalence, and mortality makes it a compelling case for targeted federal investment.

Conclusion

The data assembled here show that kidney disease in Alaska is not just a medical issue but a public health emergency driven by poverty, structural racism, geographic isolation, and decades of underinvestment in prevention. The state leads the nation in growth of CKD incidence, prevalence, and mortality over 30 years. More than 1,000 Alaskans live with kidney failure, tens of thousands more have chronic kidney disease without knowing it, and there are no in-state transplant centers. Those most affected — Alaska Native, low-income, and rural residents — face the steepest barriers to care.
The evidence is consistent: prevention works but remains underused; diabetes and hypertension cause nearly three-quarters of kidney failure, and while blood sugar testing improved from 54% skipping tests in 2021 to 24% in 2024, gaps persist. Racial disparities are widening, with Black Americans’ relative risk rising from 3.4x to 4.3x, and American Indian and Alaska Native communities carrying compounded burdens of disease and limited access. Dialysis brings financial devastation — over 80% cannot work and out-of-pocket costs exceed 28% of income — with charity only partly filling the gap. Geography intensifies every challenge, from villages reachable only by small aircraft to homes without water or sewer. Studies like GOCADAN and Providence cohorts show that steady primary care reduces harm.
Alaska’s trajectory is not inevitable. Rising CKD, higher mortality, and widening inequities reflect preventable failures in prevention, infrastructure, and equity — and point clearly to where urgent intervention is needed most.